MindMed Inc.

NEO: MMED, OTCQB:MMEDF, DE: BGHM

Company Overview

Mind Medicine (MindMed) Inc. is a neuro-pharmaceutical company that discovers, develops and deploys psychedelic inspired medicines to improve health, promote wellness and alleviate suffering.

The company’s immediate priority is to address the opioid crisis by developing a non-hallucinogenic version of the psychedelic ibogaine. In addition, the company has established a microdosing division to conduct clinical trials of LSD microdosing for Adult ADHD, is pursuing experiential psychedelic assisted therapy for the treatment of anxiety, and is collaborating on a clinical trial to evaluate LSD for the treatment of cluster cluster headaches.

The MindMed executive team brings extensive biopharmaceutical industry experience to this groundbreaking approach to the development of next-generation psychedelic medicines. 

Management Team

Mr. Stephen L. Hurst
Co-founder, Exec. Chair, Co-CEO & Sec.

Mr. Jamon Alexander Rahn
Co-Founder, Co-CEO & Director

Dr. Scott M. Freeman
Co-Founder, Pres & Chief Medical Officer

Mr. Leonard Latchman
Co-founder

Mr. David Dean Guebert
Chief Financial Officer

Sign Up for Alerts

Receive an email alert every time a company announces a merger, capital raise or files for an IPO.

Key Highlights

Market Capitalization
$65,232,716

Shares Outstanding
197,619,008